Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Katharina Beyer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7578-280X; OpenAlex author ID A5102880257. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
43
Papers, trials and grants by year

2016: 2 papers · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 4 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 14

  1. [Nationwide implementation of surgical resection for locally advanced pancreatic cancer-Feasible and safe?] First author DOI 10.1007/s00104-026-02548-4↗
  2. Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144. Co-author DOI 10.1007/s00432-022-04518-9↗
  3. Performance of the 7 th and 8 th Editions of the American Joint Committee on Cancer Staging System in Patients with Intraductal Papillary Mucinous Neoplasm-Ass… Co-author DOI 10.1097/sla.0000000000005313↗
  4. Targeting Interleukin-6/Glycoprotein-130 Signaling by Raloxifene or SC144 Enhances Paclitaxel Efficacy in Pancreatic Cancer. Co-author DOI 10.3390/cancers15020456↗
  5. The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms24032160↗
  6. Thymidine phosphorylase induction by ionizing radiation antagonizes 5-fluorouracil resistance in human ductal pancreatic adenocarcinoma. Co-author DOI 10.1007/s00411-022-00962-w↗
  7. Toward an Optimized Staging System for Pancreatic Ductal Adenocarcinoma: A Clinically Interpretable, Artificial Intelligence-Based Model. Co-author DOI 10.1200/cci.21.00001↗
  8. Peptide Signatures for Prognostic Markers of Pancreatic Cancer by MALDI Mass Spectrometry Imaging. Co-author DOI 10.3390/biology10101033↗
  9. Rethinking the TNM Classification Regarding Direct Lymph Node Invasion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14010201↗
  10. Novel methods for in vitro modeling of pancreatic cancer reveal important aspects for successful primary cell culture. Co-author DOI 10.1186/s12885-020-06929-8↗
  11. LPS promotes resistance to TRAIL-induced apoptosis in pancreatic cancer. Co-author DOI 10.1186/s13027-017-0139-4↗
  12. Subdiaphragmatic vagotomy promotes tumor growth and reduces survival via TNFα in a murine pancreatic cancer model. Co-author DOI 10.18632/oncotarget.15019↗
  13. Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by beta-adrenergic receptor blockade. Co-author DOI 10.1016/j.pan.2016.03.005↗
  14. TRAIL Promotes Tumor Growth in a Syngeneic Murine Orthotopic Pancreatic Cancer Model and Affects the Host Immune Response. Co-author DOI 10.1097/mpa.0000000000000469↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Carsten Kamphues · 7 shared papers, 2020–2023 · strength 0.93
  2. Georgios Antonios Margonis · 6 shared papers, 2020–2023 · strength 0.77
  3. Michael Hoffmann · 1 shared paper, 2026 · strength 0.63
  4. Ioannis Pozios · 4 shared papers, 2021–2023 · strength 0.63
  5. Hendrik Seeliger · 4 shared papers, 2021–2023 · strength 0.60
  6. Florian Nino Loch · 4 shared papers, 2020–2023 · strength 0.53
  7. Nina A. Hering · 2 shared papers, 2023 · strength 0.36
  8. Christiane J. Bruns · 2 shared papers, 2022–2023 · strength 0.33
  9. Mihnea Paul Dragomir · 2 shared papers, 2021–2023 · strength 0.30
  10. Simon Schallenberg · 2 shared papers, 2021–2023 · strength 0.30
  11. Wolfram von Bernstorff · 4 shared papers, 2016–2017 · strength 0.25
  12. Lars Ivo Partecke · 4 shared papers, 2016–2017 · strength 0.25
  13. Alessandra Pulvirenti · 2 shared papers, 2021–2023 · strength 0.24
  14. Christopher Lee Wolfgang · 2 shared papers, 2021–2023 · strength 0.24
  15. Matthew John Weiss · 2 shared papers, 2021–2023 · strength 0.24
  16. Frederick Klauschen · 2 shared papers, 2020–2021 · strength 0.23
  17. Frank Ulrich Weiß · 3 shared papers, 2016–2017 · strength 0.19
  18. Thomas Knösel · 1 shared paper, 2023 · strength 0.18
  19. André Käding · 3 shared papers, 2016–2017 · strength 0.17
  20. Carlos F. Fernandez-del Castillo · 1 shared paper, 2023 · strength 0.15
  21. Peter J. Allen · 1 shared paper, 2023 · strength 0.15
  22. Kevin C. Soares · 1 shared paper, 2023 · strength 0.15
  23. Vicente Morales‐Oyarvide · 1 shared paper, 2023 · strength 0.15
  24. Lucas D. Lee · 1 shared paper, 2022 · strength 0.15
  25. Oliver Klein · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.